We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
KALA BIO Inc | NASDAQ:KALA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.81 | 6.70 | 7.09 | 0 | 01:00:00 |
|
Delaware
|
| |
27-0604595
|
|
|
(State or other jurisdiction of
incorporation or organization) |
| |
(I.R.S. Employer
Identification Number) |
|
|
Stuart M. Falber
Scott N. Lunin Wilmer Cutler Pickering Hale and Dorr LLP 60 State Street Boston, MA 02109 Telephone: (617) 526-6000 |
| |
Eric L. Trachtenberg
General Counsel, Chief Compliance Officer and Corporate Secretary Kala Pharmaceuticals, Inc. 1167 Massachusetts Avenue Arlington, MA 02476 Telephone: (781) 996-5252 |
|
| Large accelerated filer | | | ☐ | | | Accelerated filer | | | ☐ | |
| Non-accelerated filer | | | ☒ | | | Smaller reporting company | | | ☒ | |
| | | | | | | Emerging growth company | | | ☐ | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 11 | | | |
| | | | 15 | | | |
| | | | 17 | | | |
| | | | 17 | | | |
| | | | 18 | | | |
| | | | 18 | | |
|
Common Stock Offered by Selling Stockholders
|
| | 5,391,213 shares, consisting of 76,813 outstanding shares of our common stock and 5,314,400 shares of our common stock issuable upon the conversion of outstanding shares of Series E Preferred Stock. | |
|
Use of Proceeds
|
| | We will not receive any proceeds from the sale of shares in this offering. | |
|
Risk Factors
|
| | You should read the “Risk Factors” section of this prospectus and in the documents incorporated by reference in this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. | |
|
Nasdaq Capital Market Symbol
|
| | “KALA” | |
|
SEC registration fee
|
| | | $ | 6,381 | | |
|
Legal fees and expenses
|
| | | $ | 40,000 | | |
|
Accounting fees and expenses
|
| | | $ | 20,000 | | |
|
Printing fees and expenses
|
| | | $ | 3,000 | | |
|
Miscellaneous fees and expenses
|
| | | $ | 5,619 | | |
|
Total expenses
|
| | | $ | 75,000 | | |
Exhibit No.
|
| |
Description
|
|
4.4
|
| | Registration Rights Agreement, dated March 2, 2023, by and among the Registrant and the other parties thereto (incorporated by reference to Exhibit 4.5 to the Registrant’s annual report on Form 10-K (File No. 001-38150) filed on March 3, 2023). | |
5.1
|
| | | |
23.1
|
| | | |
23.2
|
| | | |
24.1
|
| | | |
107
|
| | |
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ MARK IWICKI
Mark Iwicki
|
| |
Chief Executive Officer and
Chairman of Board of Directors (Principal Executive Officer) |
| |
March 3, 2023
|
|
|
/s/ MARY REUMUTH
Mary Reumuth
|
| |
Chief Financial Officer
(Principal Financial and Accounting Officer) |
| |
March 3, 2023
|
|
|
/s/ MARK S. BLUMENKRANZ
Mark S. Blumenkranz, M.D.
|
| |
Director
|
| |
March 3, 2023
|
|
|
/s/ MARJAN FARID
Marjan Farid, M.D.
|
| |
Director
|
| |
March 3, 2023
|
|
|
/s/ ANDREW I. KOVEN
Andrew I. Koven
|
| |
Director
|
| |
March 3, 2023
|
|
|
/s/ C. DANIEL MYERS
C. Daniel Myers
|
| |
Director
|
| |
March 3, 2023
|
|
|
/s/ ROBERT PAULL
Robert Paull
|
| |
Director
|
| |
March 3, 2023
|
|
|
/s/ GREGORY PERRY
Gregory Perry
|
| |
Director
|
| |
March 3, 2023
|
|
|
/s/ HOWARD B. ROSEN
Howard B. Rosen
|
| |
Director
|
| |
March 3, 2023
|
|
1 Year KALA BIO Chart |
1 Month KALA BIO Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions